TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05600244

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENG block Technique
Description: A linear probe will be used. Puncture will be performed in a lateromedial direction until the needle tip reached the plane between the iliopsoas tendon and periosteum and between the anterior inferior iliac spine and iliopubic eminence. After a negative aspiration test, 30 ml of bupivacaine 0.25% will be injected in the plane beneath the iliopsoas muscle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar ESPB Technique
Description: Using the out-plane technique, a 22G/80-mm block needle will be advanced until it reached the transverse process. 0.5-1 ml of the prepared local anesthetic solution, 30 ml bupivacaine 0.25% will be administered leading to hydrodissection to confirm the correct location. The needle will be repositioned by pulling back a few millimeters if resistance occurs when administering local anesthetic . All local anesthetic will be administered to this location between the transverse process and the erector spinae muscle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transmuscular QLB-t block Technique
Description: A convex transducer will be placed in the transverse plane on the flank of the patient cranial to the iliac crest. The 4th lumbar vertebral transverse process, erector spinae muscles, psoas muscle, transverse abdominis muscle, internal and externa oblique muscles, and the quadratus lumborum muscle will be identified. A 15 cm 22G insulated needle will be inserted on the posterior corner of the transducer. 30 ml bupivacaine 0.25% will be administered between the quadratus lumborum and psoas muscles into the fascial plane.
Study: NCT05668598

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ecological MAI test
Description: Neuropsychological assessment will be realize to determine presence or absence of neurodegenerative disease.~Study test is ecological MAI.
Study: NCT04751812

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-pain opioid free
Description: Paracetamol, Etoricoxib, Ondansetron p.o. Betamethasone 4 mg iv.~Anesthesia:~Infusion Dexmedetomidin 0.2 mikrogram/kg/h iv started 5 min before induction Induction: Esketamin 0.1mg/kg + Propofol 1.5-2 mg/kg iv + rocuronium 0.5 mg/kg iv Start of surgery: Esketamin 0.1 mg/kg iv. Maintenance of anesthesia: Sevoflurane Dexmedetomidin inf 0.2 mikrogram/kg/h Esketamin inf 0.1-0.3mg/kg/h and 0.1 mg/kg adjusted after BP and HR 30 min before end of surgery Lidocaine 1 mg/kg iv~Postoperative pain treatment:~• Dexmedetomidin (inf 01-0.2 µg/kg/h) 4 hours postoperative~If pain NRS ≧3 Esketamin 0.1mg/kg iv + Lidocain 0.5 mg/kg iv (max 4 mg/kg /4 h) If pain NRS ≧3 within 30 min after treatment above is given with Esketamin + Lidocain, 2.5 mg Oxycodone iv. is given and may be repeated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Paracetamol, Etoricoxib, Oxycodone, Ondansetron p.o. Betamethasone 4 mg iv.~Anesthesia:~Target controlled infusion (TCI) with doses of propofol and remifentanil based on age, weight and height. Oxycodone 0.1 mg/kg 30 minutes before cessation of remifentanil.~Postoperative care:~At pain NRS ≥ 4 - 5 mg of oxycodone i.v. Paracetamol will be administered every 6 hours. If above is not sufficient bolus Clonidine 1 µg/kg i.v.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Paracetamol, Etoricoxib, Oxycodone, Ondansetron p.o. Betamethasone 4 mg iv.~Anesthesia:~Target controlled infusion (TCI) with doses of propofol and remifentanil based on age, weight and height. Oxycodone 0.1 mg/kg 30 minutes before cessation of remifentanil.~Postoperative care:~At pain NRS ≥ 4 - 5 mg of oxycodone i.v. Paracetamol will be administered every 6 hours. If above is not sufficient bolus Clonidine 1 µg/kg i.v.
Study: NCT06361680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 Cap/Tab as natural factors capsules or kirkman tablets
Description: Group A will take Soft gel capsules or tablets of Coenzyme Q10 in a dose of 100-200mg of natural factors or kirkman but group B will not take Coenzyme Q10 just observe them

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 Cap/Tab as natural factors capsules or kirkman tablets
Description: Group A will take Soft gel capsules or tablets of Coenzyme Q10 in a dose of 100-200mg of natural factors or kirkman but group B will not take Coenzyme Q10 just observe them
Study: NCT05511389

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anterolateral electrode position
Description: As described previously

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anteroposterior electrode position
Description: As described previously

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual pressure
Description: Manual pressure applied to the anterior electrode

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual pressure
Description: Manual pressure applied to the anterior electrode
Study: NCT05851729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kegal exercises with postural correction
Description: Kegal exercises with postural correction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kegal exercises without postural correction
Description: Kegal exercises without postural correction
Study: NCT06437210

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Viusid Oral Solution
Description: Patients in the experimental intervention group will be administered Viusid Oral Solution (CATALYSIS S.L., Madrid, Spain) 30 mL orally 3 times a day with the main meals (breakfast, lunch and dinner) for 30 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the experimental intervention group will be administered Placebo (CATALYSIS S.L., Madrid, Spain) 30 mL orally 3 times a day with the main meals (breakfast, lunch and dinner) for 30 days.
Study: NCT04759196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topamax
Description: TPM : 50 mg BID, with increased of 50 mg by week until efficacy, to a maximum of 100 mg BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topamax
Description: TPM : 50 mg BID, with increased of 50 mg by week until efficacy, to a maximum of 100 mg BID.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: LEV : 500 mg BID, with increase of 1000 mg die divided in two doses each week until efficacy, to a maximum of 1500 mg BID.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: LEV : 500 mg BID, with increase of 1000 mg die divided in two doses each week until efficacy, to a maximum of 1500 mg BID.
Study: NCT05711420

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamification method group
Description: Gamification method group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flipped learning group
Description: Flipped learning group
Study: NCT04408495

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention group_MRA
Description: Tidal Volume (Vt) =6-8 mL/kg of predicted body weight (PBW), Peep=8 cmH2O, recruitment maneuvers=30cm H2O every 30 min after intubation (except during CPB), after any disconnection and at the admission in ICU.~Recruitment maneuvers are performed in accordance with the surgical team an if SAP≥90 mmHg or MAP≥65 mmHg.~Ventilation is maintained during CPB Vt=2.5 mL/kg, Peep= 5 cmH2O

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Vt=6-8 mL/kg of PBW, Peep=5 cmH2O , No recruitment maneuvers. Ventilation maintained during CPB Vt=2.5 mL/kg, Peep= 5 cmH2O.
Study: NCT06724835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XKDCT293
Description: Autologous targeted Nectin4 chimeric antigen receptor T cell injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAR-T cell
Description: Nectin-4-CAR-T
Study: NCT06724458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: All arms will involve participants performing resistance exercise bouts of the described exercises. at the given loads, and with the stated flow condition
Study: NCT05204706

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MyManis app
Description: The women will receive a brochure outlining the app features and step guide on how to download the app which will be available in both Bahasa Melayu and English languages. A link to download the app via text message will also be sent to participants for convenience. Once the app has been downloaded, participants will be invited to set up an account. Once completed this will give them full access to the MyManis app. The key component of MyManis app content presented under six main tabs which are homepage, information, diet, exercise, wellbeing and GDM monitoring. The women will be invited to join group peer support through WhatsApp facilitated by a dietitian trained in motivational interviewing. The women will be notified via text message if an update of the app is required. If there's women who have not accessed the app for over a two-week period will be flagged and a notification will be sent via the app to motivate app engagement.
Study: NCT06724458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: All arms will involve participants performing resistance exercise bouts of the described exercises. at the given loads, and with the stated flow condition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: All arms will involve participants performing resistance exercise bouts of the described exercises. at the given loads, and with the stated flow condition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: All arms will involve participants performing resistance exercise bouts of the described exercises. at the given loads, and with the stated flow condition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: All arms will involve participants performing resistance exercise bouts of the described exercises. at the given loads, and with the stated flow condition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: All arms will involve participants performing resistance exercise bouts of the described exercises. at the given loads, and with the stated flow condition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: All arms will involve participants performing resistance exercise bouts of the described exercises. at the given loads, and with the stated flow condition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: All arms will involve participants performing resistance exercise bouts of the described exercises. at the given loads, and with the stated flow condition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: All arms will involve participants performing resistance exercise bouts of the described exercises. at the given loads, and with the stated flow condition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: All arms will involve participants performing resistance exercise bouts of the described exercises. at the given loads, and with the stated flow condition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: All arms will involve participants performing resistance exercise bouts of the described exercises. at the given loads, and with the stated flow condition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: All arms will involve participants performing resistance exercise bouts of the described exercises. at the given loads, and with the stated flow condition
Study: NCT06723236

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGC028
Description: MGC028 is an antibody-drug conjugate targeted against ADAM9.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGC028
Description: MGC028 is an antibody-drug conjugate targeted against ADAM9.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGC028
Description: MGC028 is an antibody-drug conjugate targeted against ADAM9.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGC028
Description: MGC028 is an antibody-drug conjugate targeted against ADAM9.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGC028
Description: MGC028 is an antibody-drug conjugate targeted against ADAM9.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGC028
Description: MGC028 is an antibody-drug conjugate targeted against ADAM9.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGC028
Description: MGC028 is an antibody-drug conjugate targeted against ADAM9.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGC028
Description: MGC028 is an antibody-drug conjugate targeted against ADAM9.
Study: NCT06722352

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palliative Care Training
Description: Teaching about caring for individuals with
Study: NCT05653882

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AB248
Description: Intravenous infusion of AB248: CD8+ T cell selective interleukin-2 investigational drug

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AB248
Description: Intravenous infusion of AB248: CD8+ T cell selective interleukin-2 investigational drug

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AB248
Description: Intravenous infusion of AB248: CD8+ T cell selective interleukin-2 investigational drug

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AB248
Description: Intravenous infusion of AB248: CD8+ T cell selective interleukin-2 investigational drug

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Intravenous infusion of pembrolizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Intravenous infusion of pembrolizumab
Study: NCT05644145

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Serological study after yellow fever vaccination
Description: It is a serological survey of the cohort of children who participated in the preliminary investigation and seroconverted after vaccination against yellow fever.
Study: NCT06518616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10-day meditation intervention
Description: prerecorded meditation units delivered by smartphone app

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 10-day health education intervention
Description: prerecorded health education units delivered by smartphone app
Study: NCT05269225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Organic diet
Description: Organically produced foods.
Study: NCT05360563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based physical training
Description: Patients allocated to this group will participate in a 16-week home-based physical training program, structured in three weekly sessions of aerobic and muscle strengthening exercises (which also have components that stimulate flexibility and balance). A third of the weekly physical training sessions will be supervised via telemedicine (with video call) by a clinical exercise specialist, but all patients will have illustrated exercise booklets and a full-time remote support service available for the remaining sessions (via text or voice messages).
Study: NCT05269225

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional diet
Description: Conventionally produced foods.
Study: NCT06525987

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical activity
Description: Randomization to a 24-week physical exercise program
Study: NCT05409586

Intervention type: PROCEDURE
Intervention: segmental mastectomy
Description: The preferred method in the treatment of some patients diagnosed with IGM

Intervention type: PROCEDURE
Intervention: segmental mastectomy
Description: The preferred method in the treatment of some patients diagnosed with IGM
Study: NCT06416345

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cue2Walk
Description: 24 weeks of using of the Cue2Walk device in the own living environment + 8 weeks of naturalistic follow-up

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: 24 weeks of receiving usual care + 8 weeks of using of the Cue2Walk device in the own living environment
Study: NCT04911738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality , immersion in a virtual titlted room
Description: The immersion in virtual reality will be based on the HTC VIVE® device and the software developed by the Virtualis Society.
Study: NCT06524193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telepractice group voice therapy
Description: * Voice therapy delivered in group basis via telepractice.~* The voice therapy program will include both indirect and direct voice therapy, in accordance with the current best practice recommendations. Indirect voice therapy will include information counselling on voice production and disorder and vocal hygiene. Direct voice therapy will adopt the resonant voice therapy approach and also head and neck relaxation exercises, which has shown to be effective for muscle tension dysphonia.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face group voice therapy
Description: * Voice therapy that will be delivered in group basis in-person with patients.~* The voice therapy program will include both indirect and direct voice therapy, in accordance with the current best practice recommendations. Indirect voice therapy will include information counselling on voice production and disorder and vocal hygiene. Direct voice therapy will adopt the resonant voice therapy approach and also head and neck relaxation exercises, which has shown to be effective for muscle tension dysphonia.
Study: NCT06525987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Randomization to a 24-week physical exercise program
Study: NCT06526104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Priming dose of tremelimumab 300 mg IV once (Cycle 1, Day 1 only)
Study: NCT06237153

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Triamcinolone Acetonide extended release suspension
Description: Active steroid
Study: NCT05159037

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gaze Contingent Music Reward Therapy
Description: Feedback according to participants' viewing patterns, in order to modify their attention.
Study: NCT06237153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide extended release suspension
Description: Active steroid
Study: NCT05180435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Meals
Description: A family-based multicomponent lifestyle modification intervention with the goal to increase the frequency of family meals and meet physical activity recommendations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: A family-based multicomponent lifestyle modification intervention with the goal to increase the consumption of fruits and vegetables and and meet physical activity recommendations.
Study: NCT05217550

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Veggie Brek
Description: Offering vegetables to children at breakfast alongside their main breakfast food for three consecutive weeks (five days a week) between baseline and follow-up weeks where vegetables are also offered to children at breakfast alongside their main breakfast food for five days a week.
Study: NCT05159037

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Gaze Contingent Music Reward Therapy
Description: Feedback according to participants' viewing patterns, in order to modify their attention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Booster
Description: Participants listen to a musical track they ranked as highly liked before a stressful situation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Music Booster
Description: Participants listen to a musical track they ranked as highly liked before a stressful situation
Study: NCT06264388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB107-RRV
Description: Patients will undergo surgery to remove as much of the high-grade glioma (HHG) tumor as possible and will receive combination intravenous (IV) and adaptive repeat intratumoral delivery of DB107-RRV in the vein (IV) and in the walls of the cavity that remains where tumor is removed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB107-FC
Description: Patients will start taking DB107-FC three times by mouth every day for a period of seven days, which is one cycle of treatment. A cycle of treatment is medication taken on a set schedule with periods of rest in between. Patients will wait five weeks before taking the next seven day course of DB107-FC. The first dose of DB107-FC will be taken at the hospital or clinic; afterward, patients will take the doses of DB107-FC at home. Patients will take DB107-FC for up to 12 months after surgery.
Study: NCT06526104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg IV on Day 1 of each 4-week cycle.
Study: NCT04978129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online and Text Messaging Intervention
Description: The online and TM intervention, and its delivery, will be designed and adapted based on the results of the formative focus groups and cognitive interviews and is meant to be non-confrontational in tone, seeks to increase motivation to increase the quality use of PBS and decrease motivations for non-use of PBS.
Study: NCT05482646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: The Tai Chi intervention will be prescribed as a 3-month program with two 1.5-h sessions weekly instructed by qualified Tai Chi instructors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise
Description: The conventional exercise intervention will be prescribed as a 3-month program with two 1.5-h sessions of generic fitness training weekly instructed by qualified instructors.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Education Control
Description: Participants in the control group will participate in a health education program delivered by research personnel.
Study: NCT06487806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SmokefreeSGM
Description: Participants will be asked to set a quit date within the next 15 days before being enrolled in the SmokefreeSGM Español text messaging program. They will be mailed a 6-week supply of nicotine patches. The participants will get daily text messages for 6 weeks that will encourage them to quit smoking.
Study: NCT05868187

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise, Problem-Solving Session and Education
Description: Complete assigned exercises three times a week Complete Action plan co-developed Complete part or all of one of the four interactive educational modules